Thesis abstract:

This PhD project aims to uncover the origins of resistance in melanoma tumours by studying the tumour microenvironment (TME). By identifying tumour-specific cell clones, the project seeks to improve the prediction of treatment responses and develop innovative combination therapies for clinical trials, enhancing neoadjuvant therapy outcomes.

The study focuses on understanding the unique molecular characteristics of resistance genotypes to refine clinical trial designs and identify subgroups of non-responders needing personalised therapies. It also investigates the biological mechanisms of tumour recurrence and drug resistance in metastatic melanoma, offering insights into immunotherapy resistance niches. This integrated approach combines bioinformatics, single-cell sequencing, and advanced imaging techniques to enhance therapeutic strategies for melanoma patients.